Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
Go back to Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'| (NASDAQ: IOVA) | Delayed: 6.98 +0.46 (7.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $6.52 | 52 Week High | $ | |||
| Open | $6.52 | 52 Week Low | $ | |||
| Day High | $7.00 | P/E | N/A | |||
| Day Low | $6.36 | EPS | $ | |||
| Volume | 17,484,122 | |||||
| Rider Explorations, Inc. (NASDAQ: REPL) | Delayed: 14.97 -0.22 (1.45%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.19 | 52 Week High | $1.45 | |||
| Open | $15.19 | 52 Week Low | $0.50 | |||
| Day High | $15.39 | P/E | N/A | |||
| Day Low | $14.69 | EPS | $0.00 | |||
| Volume | 2,398,383 | |||||

